Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Acta Paediatr ; 112(7): 1565-1573, 2023 07.
Article in English | MEDLINE | ID: mdl-36951625

ABSTRACT

AIM: To systematically review the clinical features and outcomes of paediatric patients developing neurological complications associated with a rotavirus infection. METHODS: A systematic literature review and meta-analysis was performed, including articles published from 1984 to 2020. Neurological complications were classified into four groups: encephalitis, cerebellitis, encephalo-cerebellitis and benign convulsions with mild gastroenteritis (CwG). RESULTS: Out of 68 reports that fulfilled the research criteria, 99 cases of CwG, 39 cases of encephalitis, 18 cases of encephalo-cerebellitis and five cases of cerebellitis were collected. Ninety-five patients were from Asia. Median age was 22 (IQR 14-29) months, and the children who developed CwG were significantly younger (19, IQR 12-24 months, p < 0.0001) than the others. Status epilepticus was observed in 23% and 5% of the encephalitis and CwG groups respectively. The most frequently described neuroimaging finding were lesions of the splenium of corpus callosum. Four deaths were reported in the encephalitis group, whereas no fatal events were described in the other groups. Among the surviving children, the encephalo-cerebellitis group showed the most severe long-term outcome. All cases of CwG recovered completely. CONCLUSION: Older age at diagnosis and the development of encephalo-cerebellitis are associated with a higher risk of long-term complications.


Subject(s)
Encephalitis , Gastroenteritis , Rotavirus Infections , Rotavirus , Humans , Child , Young Adult , Adult , Rotavirus Infections/complications , Rotavirus Infections/diagnosis , Gastroenteritis/complications , Seizures/etiology , Neuroimaging
2.
Cancer Radiother ; 24(2): 120-127, 2020 Apr.
Article in English | MEDLINE | ID: mdl-32173269

ABSTRACT

BACKGROUND: The main complication after hypofractionated radiotherapy for lung carcinoma is radiation-induced lung toxicity, which can be divided into radiation pneumonitis (acute toxicity, occurring within 6 months) and lung fibrosis (late toxicity, occurring after 6 months). The literature describes several predictive factors related to the patient, to the tumor (volume, central location), to the dosimetry and to biological factors. MATERIALS AND METHODS: This study is a retrospective analysis of 90 patients treated with stereotactic body irradiation for stage I non-small-cell lung carcinoma between December 2010 and May 2015. RESULTS: Radiation pneumonitis was observed in 61.5% of the patients who were mainly asymptomatic (34%). Chronic obstructive pulmonary disease was not predictive of radiation pneumonitis, whereas active smoking was protective. Centrally located tumors were not more likely to result in this complication if the radiation schedule utilized adapted fractionation. In our study, no predictive factor was identified. Whereas the mean lung dose was a predictive factor in 3D radiotherapy, the lung volume irradiated at high doses seemed to be involved in the pathogenesis after hypofractionated radiotherapy. CONCLUSION: The discovery of predictive factors for radiation pneumonitis is difficult due to the rarity of this complication, especially with an 8×7.5Gy schedule. Radiation pneumonitis seems to be correlated with the volume irradiated at high doses, which is in contrast to the known knowledge about the organs in parallel. This finding leads us to raise the hypothesis that vessel damage, organs in series, occurring during hypofractionated radiotherapy could be responsible for this toxicity.


Subject(s)
Carcinoma, Non-Small-Cell Lung/radiotherapy , Lung Neoplasms/radiotherapy , Lung/radiation effects , Radiation Pneumonitis/etiology , Radiosurgery/adverse effects , Radiotherapy, Intensity-Modulated/adverse effects , Aged , Aged, 80 and over , Analysis of Variance , Angiotensin Receptor Antagonists/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Carcinoma, Non-Small-Cell Lung/pathology , Female , Humans , Lung Neoplasms/pathology , Male , Middle Aged , Models, Theoretical , Pulmonary Disease, Chronic Obstructive/complications , Pulmonary Fibrosis/etiology , Pulmonary Fibrosis/prevention & control , Radiation Pneumonitis/prevention & control , Radiosurgery/methods , Retrospective Studies , Smoking
3.
Ann Oncol ; 23(8): 2072-2077, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22219016

ABSTRACT

BACKGROUND: Data are limited regarding bone metastases from colorectal cancer (CRC). The objective of this study was to survey the natural history of bone metastasis in CRC. PATIENTS AND METHODS: This retrospective, multicenter, observational study of 264 patients with CRC involving bone examined cancer treatments, bone metastases characteristics, skeletal-related event (SRE) type and frequency, zoledronic acid therapy, and disease outcomes. RESULTS: Most patients with bone metastases had pathologic T3/4 disease at CRC diagnosis. The spine was the most common site involved (65%), followed by hip/pelvis (34%), long bones (26%), and other sites (17%). Median time from CRC diagnosis to bone metastases was 11.00 months; median time to first SRE thereafter was 2.00 months. Radiation and pathologic fractures affected 45% and 10% of patients, respectively; 32% of patients had no reported SREs. Patients survived for a median of 7.00 months after bone metastases diagnosis; SREs did not significantly affect survival. Subgroup analyses revealed that zoledronic acid significantly prolonged median time to first SRE (2.00 months versus 1.00 month, respectively, P=0.009) and produced a trend toward improved overall survival versus no zoledronic acid. CONCLUSION: This study illustrates the burden of bone metastases from CRC and supports the use of zoledronic acid in this setting.


Subject(s)
Bone Neoplasms/secondary , Colorectal Neoplasms/pathology , Bone Density Conservation Agents/therapeutic use , Bone Neoplasms/drug therapy , Colorectal Neoplasms/drug therapy , Diphosphonates/therapeutic use , Humans , Imidazoles/therapeutic use , Retrospective Studies , Zoledronic Acid
5.
Int J Pediatr Otorhinolaryngol ; 25(1-3): 209-16, 1993 Jan.
Article in English | MEDLINE | ID: mdl-8436467

ABSTRACT

Neonatal respiratory distress is a commonly seen entity whose causes are legion. Nasal obstruction secondary to intranasal masses is significant because neonates are obligate nasal breathers. Congenital nasolacrimal duct obstruction (NLDO) causing respiratory distress is an extremely rare event since most cases of NLDO do not compromise the nasal airway. We report two cases of neonatal respiratory distress secondary to bilateral NLDO with cystic mucocele formation and intranasal extension; only two similar cases have been previously described. Pertinent embryology and anatomy are reviewed as is a brief discussion of congenital NLDO. MRI and a nasal endoscopic photograph are provided demonstrating the nasolacrimal and nasal pathology. Treatment strategies are outlined. Consideration of nasolacrimal duct pathology in the differential diagnosis of neonatal respiratory distress and nasal obstruction is stressed.


Subject(s)
Lacrimal Duct Obstruction/congenital , Mucocele/congenital , Nasal Obstruction/etiology , Nasolacrimal Duct , Respiratory Insufficiency/etiology , Female , Humans , Infant, Newborn , Male
7.
Psychopathology ; 25(6): 331-4, 1992.
Article in English | MEDLINE | ID: mdl-1363443

ABSTRACT

To assess clinical predictors of 1-year outcome in schizophrenia, 63 patients were studied prospectively. Persistent negative and total symptoms after 4 weeks of neuroleptic treatment accounted for 62% of the variance of 1-year outcome, whereas baseline measures showed no relationship to outcome. Thus, 1-year outcome in schizophrenia can be reasonably predicted on the basis of symptoms persisting after 4 weeks of treatment.


Subject(s)
Schizophrenic Psychology , Adult , Antipsychotic Agents/therapeutic use , Female , Humans , Male , Prognosis , Prospective Studies , Psychiatric Status Rating Scales , Regression Analysis , Schizophrenia/drug therapy , Schizophrenia/physiopathology
8.
Biol Psychiatry ; 29(10): 953-64, 1991 May 15.
Article in English | MEDLINE | ID: mdl-1676605

ABSTRACT

To relieve confusion about the clinical correlates and prognostic implications of the dexamethasone suppression test (DST) in schizophrenia, we conducted a DST in 44 schizophrenic inpatients at drug-free baseline and approximately 4 weeks after neuroleptic treatment. Patients were rated on positive, negative, and depressive symptoms at both times. A head computed tomography (CT) scan was performed and measures of ventricle-brain ratio (VBR) obtained. Clinical improvement was monitored at four weeks, and longer-term outcome assessed at 1 year. Seventeen of the 44 patients were DST nonsuppressors at baseline, and five of these remained nonsuppressors at 4 weeks posttreatment. Postdexamethasone plasma cortisol levels were correlated with negative symptoms at baseline (r = 0.45; p less than 0.01), but not after 4 weeks of neuroleptic treatment. Postdexamethasone plasma cortisols were not related to global severity, positive, or depressive symptoms at either timepoint or to VBR. Persistent nonsuppression was associated with poor outcome, but baseline postdexamethasone cortisol levels were unrelated to outcome at 4 weeks and 1 year. The literature on DST in schizophrenia is reviewed and attempts are made to reconcile discrepant findings and to discuss pathophysiological implications.


Subject(s)
Cerebral Ventricles/pathology , Dexamethasone , Schizophrenia/diagnosis , Schizophrenic Psychology , Adolescent , Adult , Antipsychotic Agents/therapeutic use , Female , Humans , Hydrocortisone/blood , Male , Middle Aged , Prognosis , Psychiatric Status Rating Scales , Schizophrenia/blood , Schizophrenia/classification , Schizophrenia/drug therapy , Tomography, X-Ray Computed
10.
Am Rev Respir Dis ; 138(6): 1579-83, 1988 Dec.
Article in English | MEDLINE | ID: mdl-3059900

ABSTRACT

This study examined nonspecific airway responsiveness to methacholine (MC) after inhalation of cotton bract extract (CBE). In a randomized double-blind, crossover trial, 13 healthy volunteers underwent an MC inhalation challenge test prior to inhalation of CBE and normal saline solution (NSS) aerosol sham as well as 2, 8, 24, and 168 h (7 days) later. The response parameter was the concentration of MC required to induce a 25% decrement in the maximal expiratory flow at 40% of the vital capacity below total lung capacity on the partial expiratory flow-volume curve (PC25MEF40%(P]. Five of 13 subjects demonstrated a ventilatory response to CBE with a 20% or larger decrement in the MEF40%(P); no subject demonstrated such change with NSS. For the group, the maximal decrement in MEF40%(P) was to 76.5 +/- 20.3% of baseline (mean +/- SD), occurring approximately 60 to 90 min after provocation, whereas the largest decrement after normal saline was to 88 +/- 10.6% of baseline, occurring immediately after inhalation. Changes in airway responsiveness to MC were transient. For example, the PC25MEF40%(P) for the group (mean +/- SD) was 51.3 +/- 41.1 mg/ml at baseline and 25.8 +/- 30.3 and 52.2 +/- 57.3 mg/ml at 2 and 8 h. After a pre-sham baseline of 50.4 +/- 43.2 mg/ml, PC25MEF40%(P) was 57.6 +/- 83.8 and 153.8 +/- 148 mg/ml at 2 and 8 h. Repeated measures ANOVA on these acute, same-day changes (i.e., 2 and 8 h after provocation) demonstrated a statistically significant effect of CBE on airway responsiveness (p = 0.048). These data demonstrate that inhalation of CBE, in addition to bronchospasm, causes a transient increase in airway responsiveness.


Subject(s)
Bronchi/drug effects , Gossypium/analysis , Plant Extracts/pharmacology , Respiratory Hypersensitivity/chemically induced , Administration, Inhalation , Adolescent , Adult , Bronchial Provocation Tests , Humans , Lung/physiology , Methacholine Chloride , Methacholine Compounds , Respiration/drug effects , Respiratory Function Tests , Respiratory Hypersensitivity/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...